- Document Number:
20240335480
- Appl. No:
18/579100
- Application Filed:
July 14, 2022
- نبذة مختصرة :
An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.
- Assignees:
Astellas Pharma Inc. (Chuo-ku, Tokyo, JP), OSAKA UNIVERSITY (Suita-shi, Osaka, JP), National Center for Child Health and Development (Setagaya-ku, Tokyo, JP)
- Claim:
1. A VEGF-highly expressing pericyte-like cell obtained by a production method, comprising selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell.
- Claim:
2. The VEGF-highly expressing pericyte-like cell according to claim 1, which is obtained by a production method comprising: (a) differentiating a pluripotent stem cell into an early mesodermal cell; (b) differentiating the early mesodermal cell obtained in (a) into a pericyte-like cell; and (c) selecting a CD56(−) pericyte-like cell from a population including the pericyte-like cell.
- Claim:
3. The VEGF-highly expressing pericyte-like cell according to claim 1, which is obtained by a production method comprising: (a) differentiating a pluripotent stem cell into an early mesodermal cell; (b-1) forming a spheroid of the early mesodermal cell obtained in (a); (b-2) differentiating the early mesodermal cell forming the spheroid into a pericyte-like cell; and (c) selecting a CD56(−) pericyte-like cell from a population including the pericyte-like cell.
- Claim:
4. The VEGF-highly expressing pericyte-like cell according to claim 1, which is obtained by a production method comprising: (a) differentiating a pluripotent stem cell into an early mesodermal cell; (b-1′) forming a spheroid of the early mesodermal cell obtained in (a) in a culture vessel comprising a plurality of mortar-shaped fine wells on a culture surface without a gap; (b-2) differentiating the early mesodermal cell forming the spheroid into a pericyte-like cell; and (c) selecting a CD56(−) pericyte-like cell from a population including the pericyte-like cell.
- Claim:
5. The VEGF-highly expressing pericyte-like cell according to claim 1, wherein the pluripotent stem cell is a human pluripotent stem cell.
- Claim:
6. The VEGF-highly expressing pericyte-like cell according claim 1, wherein the pluripotent stem cell is an ES cell or an iPS cell.
- Claim:
7. A population of VEGF-highly expressing pericyte-like cells, which is selected using a cell surface marker of CD56(−) from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell.
- Claim:
8. The population of VEGF-highly expressing pericyte-like cells according to claim 7, which is selected using a cell surface marker of CD56(−) from a population including a pericyte-like cell obtained by inducing differentiation by a method comprising: (a) differentiating a pluripotent stem cell into an early mesodermal cell; and (b) differentiating the early mesodermal cell obtained in (a) into a pericyte.
- Claim:
9. The population of VEGF-highly expressing pericyte-like cells according to claim 7, which is selected using a cell surface marker of CD56(−) from a population including a pericyte-like cell obtained by inducing differentiation by a method comprising: (a) differentiating a pluripotent stem cell into an early mesodermal cell; (b-1) forming a spheroid of the early mesodermal cell obtained in (a); and (b-2) differentiating the early mesodermal cell forming the spheroid into a pericyte-like cell.
- Claim:
10. The population of VEGF-highly expressing pericyte-like cells according to claim 7, which is selected using a cell surface marker of CD56(−) from a population including a pericyte-like cell obtained by inducing differentiation by a method comprising: (a) differentiating a pluripotent stem cell into an early mesodermal cell; (b-1′) forming a spheroid of the early mesodermal cell obtained in (a) in a culture vessel comprising a plurality of mortar-shaped fine wells on a culture surface without a gap; and (b-2) differentiating the early mesodermal cell forming the spheroid into a pericyte-like cell.
- Claim:
11. The population of VEGF-highly expressing pericyte-like cells according to claim 7, wherein the pluripotent stem cell is a human pluripotent stem cell.
- Claim:
12. The population of VEGF-highly expressing pericyte-like cells according to claim 7, wherein the pluripotent stem cell is an ES cell or an iPS cell.
- Claim:
13. A pharmaceutical composition, comprising the VEGF-highly expressing pericyte-like cell according to claim 1.
- Claim:
14. A method of treating critical lower limb ischemia, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 13 to a subject in need thereof.
- Claim:
15. The method of claim 14, wherein the pharmaceutical composition is administered in combination with a vascular endothelial cell.
- Claim:
16. A pharmaceutical composition, comprising a combination of the VEGF-highly expressing pericyte-like cell according to claim 1 and a vascular endothelial cell.
- Claim:
17. A method of treating critical lower limb ischemia, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 16 to a subject in need thereof.
- Claim:
18. A method of angiogenic therapy, comprising administering a therapeutically effective amount of the VEGF-highly expressing pericyte-like cell according to claim 1 to a subject in need thereof.
- Claim:
19. A method of treating critical lower limb ischemia, comprising administering a therapeutically effective amount of the VEGF-highly expressing pericyte-like cell according to claim 1 to a subject with critical lower limb ischemia.
- Claim:
20. A pharmaceutical composition, comprising the population of VEGF-highly expressing pericyte-like cells according claim 7.
- Claim:
21. A method of treating critical lower limb ischemia, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 20 to a subject in need thereof.
- Claim:
22. The method of claim 21, wherein the pharmaceutical composition is administered in combination with a vascular endothelial cell.
- Claim:
23. A pharmaceutical composition, comprising a combination of the population of VEGF-highly expressing pericyte-like cells according claim 7 and a vascular endothelial cell.
- Claim:
24. A method of treating critical lower limb ischemia, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 23 to a subject in need thereof.
- Claim:
25. A method of angiogenic therapy, comprising administering a therapeutically effective amount of the population of VEGF-highly expressing pericyte-like cells according claim 7 to a subject in need thereof.
- Claim:
26. A method of treating critical lower limb ischemia, comprising administering a therapeutically effective amount of the population of VEGF-highly expressing pericyte-like cells according claim 7 to a subject with critical lower limb ischemia.
- Current International Class:
61; 61; 12
- الرقم المعرف:
edspap.20240335480
Processing Request
No Comments.